Overall cohort | Deleterious DDR | Wild type/VUS DDR | |
No of patients | 229 (100%) | 43 (19%) | 186 (81%) |
Age at diagnosis (years), median (range) | 60 (33–84) | 61 (33–74) | 60 (37–84) |
Gender (male) | 168 (73%) | 32 (74%) | 136 (73%) |
Nephrectomy | 218 (95%) | 41 (95%) | 177 (95%) |
Histology | |||
Clear cell RCC | 229 (100%) | 43 (100%) | 186 (100%) |
Denovo metastatic | 85 (37%) | 19 (44%) | 66 (35%) |
IMDC risk score* | |||
Favorable | 74 (34%) | 15 (39%) | 59 (34%) |
Intermediate | 113 (53%) | 20 (51%) | 93 (53%) |
Poor | 27 (13%) | 4 (10%) | 23 (13%) |
No of deleterious DDR alterations (somatic and germline) | 48 | 48 | 0 |
Somatic alterations | 35 (73%) | 35 (73%) | 0 |
Germline alterations | 13 (27%) | 13 (27%) | 0 |
*Missing for 15 patients.
DDR, DNA damage repair; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; RCC, renal cell carcinoma; VUS, variants of unknown significance.